Codexis, INC 8-K filings

Codexis announced its second quarter 2026 financial results, reporting $14.9 million in revenue and reiterating full-year guidance, alongside a successful $25 million equity capital raise.

Codexis, Inc. announced the successful closing of its public offering of common stock, raising approximately $23.1 million in net proceeds.

Codexis, Inc. announced preliminary financial results for the second quarter of 2026, expecting at least $14.8 million in revenue and approximately $54.9 million in cash.

Codexis announces board realignments including a director's resignation and subsequent re-election to rebalance board classes.

Codexis announced a strategic realignment, including a 24% workforce reduction, new CEO appointment, and a $37.8 million Merck agreement, extending its cash runway through 2027.

Codexis, Inc. announced strong second quarter 2025 financial results, exceeding analyst revenue estimates and strengthening its cash position to advance its ECO Synthesis platform.

Codexis, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the re-election of two directors and an amendment to expand the 2019 Incentive Award Plan by 8 million shares.

Codexis announced its Q1 2025 financial results, highlighting its first revenue-generating contract for ECO Synthesis manufacturing services and reiterating its full-year financial guidance.

Byron Dorgan, a Codexis board member since 2011 and former Chairman, will retire at the 2025 Annual Meeting of Stockholders.

Codexis, Inc. appoints Cynthia Collins to its Board of Directors and Compensation Committee, effective immediately.

Codexis announces its financial results for the fourth quarter and fiscal year 2024, highlighting a 4% decrease in total revenue for the year but anticipating double-digit growth in 2025.

Codexis, Inc. has appointed Christos Richards to its Board of Directors, effective immediately, as a Class II director.

Codexis has appointed Raymond De Vr to its Board of Directors and amended its bylaws to align with Delaware law and update procedural requirements.

Codexis announced positive third-quarter results, including a $31 million capital raise, key management additions, and reiterated full-year financial guidance.

Codexis, Inc. finalizes the departure of its former CFO, Sriram Ryali, with a separation agreement that includes severance, a bonus, and consulting services.

Codexis, Inc. has appointed Alison Moore as Chief Technical Officer and Georgia Erbez as Chief Financial Officer, effective September 30, 2024, leading to changes in the board and executive team.

Codexis announced its Q2 2024 financial results, reporting revenues in line with expectations and reiterating its full-year financial guidance, while also highlighting progress in its ECO Synthesis technology.

Codexis, Inc. held its 2024 annual meeting of stockholders on June 11, 2024, where directors were elected, the accounting firm was ratified, and executive compensation was approved on an advisory basis.

Codexis has successfully synthesized a full-length oligonucleotide using an enzymatic process, marking a significant step in RNA-based therapeutics manufacturing and launching new RNA ligase services.

Codexis announced a 32% year-over-year increase in total revenue for Q1 2024, driven by a 14% rise in product revenue and significant progress in its RNA synthesis platform.

Codexis, Inc. has changed its independent registered public accounting firm from BDO USA, P.C. to KPMG LLP, effective February 29, 2024.

Codexis announced its fourth quarter and full year 2023 financial results, highlighting a decrease in overall revenue but anticipating product revenue growth in 2024 and a focus on their ECO Synthesis manufacturing platform.

Codexis, Inc. announces that board member Jennifer Aaker will not seek reelection at the upcoming 2024 Annual Meeting of Stockholders.

Codexis, Inc. has entered into a loan agreement for up to $40 million with Innovatus Life Sciences, issuing warrants to purchase 424,028 shares of common stock as part of the deal.

Codexis, Inc. has amended its bylaws to modify the definition of 'Acting in Concert' and include a severability provision, effective February 8, 2024.